

BEST AVAILABLE COPY



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231 on June 16, 2000

Paige E. Snyder
Date of Signature June 16, 2000

74
RECEIVED

JUN 1 2000

TECH CENTER 1500/2300

GAU-1623

#4

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUN 17 2000
TECH CENTER 1500/2300

In re Application of: Daniel et al.

Serial No.: 09/516,728

Group Art Unit: To Be Assigned

Filed: March 1, 2000

Docket No.: 1242/12/2

For: MODULATION OF ENDOTHELIAL CELL SURFACE RECEPTOR ACTIVITY IN THE REGULATION OF ANGIOGENESIS

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the U.S. Patent and Trademark Office the following documents. A copy of each document as well as forms PTO/SB/08A and PTO/SB/08B are attached hereto. This is not to be construed as a representation that a search has been made or that a document is relevant merely because cited.

U.S. Patent No. 5,595,911 to N.K. Tonks discloses isolation of a CDNA encoding a protein tyrosine phosphatase which localizes to focal adhesions.

U.S. Patent No. 5,660,827 to Thorpe et al. discloses antibodies that bind to endoglin.

U.S. Patent No. 5,733,876 to O'Reilly et al. discloses a method of inhibiting angiogenesis.

U.S. Patent No. 5,753,230 to Brooks et al. discloses methods and compositions useful for inhibition of angiogenesis.

U.S. Patent No. 5,762,918 to Thorpe discloses methods of using steroid-polyanionic polymer-based conjugated targeted to vascular endothelial cells.

U.S. Patent No. 5,766,591 to Brooks et al. discloses methods and compositions useful for inhibition of angiogenesis.

U.S. Patent No. 5,776,427 to Thorpe et al. discloses methods for targeting the vasculature of solid tumors.

U.S. Patent No. 5,863,781 to N.K. Tonks discloses protein tyrosine phosphatase which localizes to focal adhesions.

Publication by Honda et al., entitled "Molecular Cloning, Characterization, and Chromosomal Localization of a Novel Protein-Tyrosine Phosphatase, HPTP_n", Blood, Vol. 84, (1994) pp. 4186-4194 discloses molecular cloning, characterization, and chromosomal localization of a novel protein-tyrosine phosphatase, HPTP_n.

Publication by Borges et al., entitled "Cloning and Characterization of Rat Density-Enhanced Phosphatase-1, a Protein Tyrosine Phosphatase Expressed by Vascular Cells", Circulation Research, Vol. 79, No. 3, (September 1996) pp. 570-580 discloses cloning and characterization of rat density-enhanced phosphatase-1, a protein tyrosine phosphatase expressed by vascular cells.

Publication by Keane et al., entitled "The Protein Tyrosine Phosphatase DEP-1 is Induced During Differentiation and Inhibits Growth of Breast Cancer Cells", Cancer Research, Vol. 56, (September 15, 1996) pp. 4236-4243 discloses the protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells.

Publication by Östman et al., entitled "Expression of DEP-1, a Receptor-Like Protein-Tyrosine-Phosphatase, is Enhanced with Increasing Cell Density", Proc. Natl. Acad. Sci. USA, Vol. 91, (October 1994) pp. 9680-9684 discloses the expression of DEP-1, a receptor-like protein-tyrosine-phosphatase, is enhanced with increasing cell density.

RECEIVED

PCT Application WO 91/13989 discloses methods and compositions for the treatment of malignancies in which a protein kinase is associated.

PCT Application WO 95/30008 discloses density enhanced protein tyrosine phosphatases.

PCT Application WO 98/04712 discloses substrate trapping protein tyrosine phosphatases.

PCT Application WO 99/02704 discloses dual specificity phosphatase and methods of use.

PCT Application search report for PCT Application WO 98/04712.

European Patent Application 0520029 B1 discloses methods and compositions for the treatment of malignancies in which a protein kinase is associated.

Early passage of the subject application to issue is earnestly solicited.

Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any deficiencies of payment associated with the filing of this Information Disclosure Statement to Deposit Account No. 50-0426.


Respectfully submitted,

JENKINS & WILSON, P.A.

Date:

June 16, 2000

By:



Arles A. Taylor, Jr.
Registration No. 39,395

Suite 1400 University Tower
3100 Tower Boulevard
Durham, North Carolina 27707
Telephone: (919) 493-8000
Facsimile: (919) 419-0383
1242/12/2 AAT/pes

Enclosures